Publications by authors named "Balske A"
This 2-year trial evaluated the efficacy and tolerability of a monthly oral regimen of risedronate. Postmenopausal women with osteoporosis were randomly assigned to double-blind treatment with risedronate 75 mg on 2 consecutive days each month (2CDM) or 5 mg daily. The primary end point was the percentage change from baseline in lumbar spine bone mineral density (BMD) at 12 months.
View Article and Find Full Text PDFUnlabelled: Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance.
Introduction: This 2-year, randomized, controlled, non-inferiority study assessed the efficacy and safety of a delayed-release (DR) 35-mg weekly oral formulation of risedronate that allows subjects to take their weekly risedronate dose before or immediately after breakfast.
Unlabelled: Dosing regimens of oral bisphosphonates are inconvenient and contribute to poor compliance. The bone mineral density response to a once weekly delayed-release formulation of risedronate given before or following breakfast was non-inferior to traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient regimen for oral bisphosphonate therapy.
View Article and Find Full Text PDFArticle Synopsis
- This study compared the effectiveness and side effects of different doses of risedronate (35 mg and 50 mg once a week) to a daily 5 mg dose in postmenopausal women with osteoporosis over two years.
- The primary outcome measured was the change in bone mineral density (BMD) in the lumbar spine after 12 months, with results showing that all three regimens were similarly effective.
- The findings suggest that the 35 mg once-a-week dose is optimal, as it provides the same benefits as the daily dose while being less frequent.
Background: Up to 3 years of treatment with alendronate, 5 mg/d, prevents postmenopausal bone loss.
Objective: To determine whether the effect of alendronate is sustained at 4 years of treatment and persists after treatment is discontinued.
Design: Randomized, controlled trial.
Background: Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear. Whether other antiresorptive therapies can prevent osteoporosis in these women is also not clear.
Methods: We studied the effect of 2.